Predictors for reclassification at repeat biopsy in active surveillance cohort for low-risk prostate cancer: From an interim analysis of PRIAS-JAPAN.

被引：0
|
作者：
Sugimoto, Mikio
Kakehi, Yoshiyuki
Hirama, Hiromi
Naito, Seiji
Yamaguchi, Akito
Koga, Hirofumi
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
118
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Repeat biopsy outcomes and change in QOL status at 1 year after active surveillance: Results from a Japanese multicenter prospective study and the PRIAS-JAPAN.
    Sugimoto, Mikio
    Hirama, Hiromi
    Kakehi, Yoshiyuki
    Yamaguchi, Akito
    Koga, Hirofumi
    Hashine, Katsuyoshi
    Egawa, Shin
    Miki, Jun
    Shinohara, Nobuo
    Maruyama, Satoru
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] PREDICTORS OF TRANSITION TO WATCHFUL WAITING FROM ACTIVE SURVEILLANCE AMONG MEN WITH LOW-RISK PROSTATE CANCER (FIVO COHORT)
    Carmen Mir, Maria
    Ramirez-Backhaus, Miguel
    Luis Dominguez-Escrig, Jose
    Casanova, Juan
    Iborra, Immaculada
    Collado, Argimiro
    Gomez-Ferrer, Alvaro
    Manuel Mascaros, Juan
    Rubio-Briones, Jose
    JOURNAL OF UROLOGY, 2018, 199 (04): : E210 - E211
  • [23] Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression
    Dall'Era, Marc A.
    Konety, Badrinath R.
    NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (05): : 277 - 283
  • [24] Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression
    Marc A Dall'Era
    Badrinath R Konety
    Nature Clinical Practice Urology, 2008, 5 : 277 - 283
  • [25] Longitudinal assessment of general health-related QOL in patients undergoing active surveillance (AS) for low-risk prostate cancer: Interim results of the PRIAS-JAPAN cohorts.
    Sugimoto, Mikio
    Hirama, Hiromi
    Kakehi, Yoshiyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] The impact of complications after diagnostic biopsy on repeat biopsy in men: Results from the Prostate Cancer Research International: Active surveillance (PRIAS-JAPAN) study.
    Tohi, Yoichiro
    Kato, Takuma
    Matsumoto, Ryuji
    Shinohara, Nobuo
    Yokomizo, Akira
    Mitsuzuka, Koji
    Nakamura, Masaki
    Kume, Haruki
    Sugimoto, Mikio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Active surveillance preferred for low-risk prostate cancer
    Bagcchi, Sanjeet
    LANCET ONCOLOGY, 2015, 16 (08): : E384 - E384
  • [28] Is There a Role for Active Surveillance in Low-Risk Prostate Cancer?
    Augustin, Herbert
    Mayerhofer, Katrin
    Seles, Maximilian
    Pummer, Karl
    UROLOGIA INTERNATIONALIS, 2015, 95 (02) : 125 - 131
  • [29] Active Surveillance for Low-Risk Localized Prostate Cancer
    Large, Michael C.
    Eggener, Scott E.
    ONCOLOGY-NEW YORK, 2009, 23 (11): : 974 - 979
  • [30] Dutasteride and active surveillance of low-risk prostate cancer
    Fleshner, Neil E.
    LANCET, 2012, 379 (9826): : 1590 - 1590
12345